Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | VDR | P11473 | 7/20 | 0.43 |
| ▸ | AR | P10275 | 4/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15337448 | 0.85 | XDH (0.45) | ALDH1A1 | |
| SCHEMBL19836420 | 0.83 | ACHE (0.46) | ALDH1A1CYP1A2KDM4EAGTR1LMNA | |
| SCHEMBL17708086 | 0.82 | VDR (0.49) | CYP1A2KDM4EAGTR1LMNAHTR1A | |
| SCHEMBL13182575 | 0.81 | XDH (0.53) | — | |
| SCHEMBL11497507 | 0.80 | CYP1A2 (0.65) | CYP1A2KDM4EAGTR1LMNAVDR | |
| SCHEMBL19836422 | 0.79 | SLC6A2 (0.46) | ALDH1A1CYP1A2KDM4EAGTR1LMNA | |
| SCHEMBL14934293 | 0.78 | CYP1A2 (0.54) | CYP1A2KDM4EAGTR1LMNAVDR | |
| SCHEMBL11454087 | 0.78 | HTR1A (0.63) | ALDH1A1CYP1A2KDM4EAGTR1LMNA | |
| SCHEMBL17708372 | 0.78 | ALDH1A1 (0.47) | ALDH1A1AR | |
| SCHEMBL12180774 | 0.77 | CYP1A2 (0.66) | ALDH1A1CYP1A2KDM4EAGTR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682976-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160257681-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| US-9321763-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257681-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | ALDH1A1 4361/4885CYP1A2 4423/4885KDM4E 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.